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Abstract Pentavalent antimonials are the standard treatment
for cutaneous leishmaniasis (CL) with low efficacy and
resistance is emerging. CL is increased significantly in respect
to incidence rate and expanding to new foci. In the present
study, the effect of verapamil on in vitro susceptibility of
promastigote and amastigote stages of Leishmania tropica to
meglumine antimoniate (MA, Glucantime) was evaluated
using colorimetric assay (MTT) and in a macrophage model,
respectively. Verapamil, as a calcium channel blocker, affects
drug uptake by preventing of drug efflux from the cells. In
promastigote form, several concentrations of MA with or
without verapamil showed significant decrease (P<0.05) in
optical density. The overall mean IC50 value with combina-
tion of MA plus verapamil (IC50=116.03 μg/ml) was
significantly less than MA (IC50=225.14 μg/ml) alone
(P<0.05) for promastigote stage. Similarly, the amastigote
stage was more susceptible to treatment with MA plus
verapamil to that of MA alone (P<0.05). Analysis of overall
effect of different concentrations of MA alone, compared
with combination of MA plus verapamil by mean infection
rate of amastigotes in each macrophage showed a significant
difference (P<0.05).These findings indicated some degree of
synergistic effects between MA and verapamil on in vitro
susceptibility of L. tropica to MA. Further works are required
to evaluate this synergistic effect on animal model or
volunteer human subjects.
Introduction
Leishmaniasis is still a significant cause of morbidity
and mortality in tropical and sub-tropical countries. It is
endemic in 88 countries, notably those of Southwest
Asia, and is an important public health problem in some
endemic regions including Iran. Two epidemiological
forms of cutaneous leishmaniasis (CL) are present in
Iran; anthroponotic CL, the dry, urban form, which is
caused by Leishmania tropica and zoontic CL, the wet,
rural form caused by Leishmania major. Ninety percent of
CL cases occur in seven countries: Afghanistan, Algeria,
Brazil, Iran, Peru, Saudi Arabia, and Syria (Desjeux
2004). Control measures are insufficient and complicated
by the diverse ecology of different species of sand fly
vectors and animal reservoirs. Existing treatments are
associated with adverse effects and of fairly low efficacy
(Croft et al. 2006; Firooz et al. 2006; Khatami et al. 2007;
Modabber et al. 2007). In fact, the variety of epidemio-
logical and clinical forms of leishmaniasis in the world
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makes it difficult to apply a single measure, universally
(Sharifi et al. 2010).
The first-line drugs, antimonials, are less effective
against various forms of leishmaniasis and resistance is
emerging (Jha 2006; Moreno et al. 2011; Pour et al. 2011).
For clinical and persistent cases of CL, the choice of
second-line drugs is very limited due to prolonged length of
therapy and adverse reactions (Croft et al. 2006), even
though there are promising new compounds used alone or
in combination (Moreno et al. 2011; Prasad et al. 2000;
Shakya et al. 2011; Tafaghodi et al. 2011). Treatment failure
is common in many endemic areas (Firooz et al. 2006;
Khatami et al. 2007; Modabber et al. 2007). In Iran, CL is
increased significantly and resistance is reported (Hadighi
et al. 2006, 2007; Pour et al. 2011). There is urgent need for
development of new treatment. In Leishmania species, drug
resistance is frequently associated with decreased cellular
accumulation of the drug. However, other factors such as
dose and duration of therapy, host immune status, pharma-
cological deficiencies, under-treatment, also lead to resis-
tance (Croft et al. 2006).
Verapamil, as a calcium channel blocker, affects drug
uptake by preventing drug efflux from the cells and has
been widely used for treatment of hypertension, cardiac
arrhythmia, angina pectoris, and most recently, cluster
headaches. Verapamil is also used as a vasodilator
during cryopreservation of blood vessels and as an
inhibitor of drug efflux pump proteins such as P-
glycoprotein (Bellamy 1996).
In the present study, the effect of verapamil on in vitro
susceptibility of promastigote and amastigote stages of L.
tropica to meglumine antimoniate was evaluated using




Meglumine antimoniate (MA, Glucantime Rhône–Poulenc,
France) and verapamil (V, Alborz Pharmacy, Iran) were
obtained from commercial sources. Verapamil was dis-
solved in sterile distilled water according to the manufac-
turer's instructions and aliquots stored at −20°C until use.
Verapamil at constant concentration of 8 μM was used
along with different concentrations of MA in either stage
according to the method described (Ranjini Valiathan et al.
2006). The stock solutions were defrosted and diluted in
medium just prior to assay. MA solution was stored at room
temperature and diluted in medium to prepare final
concentrations of 5.85, 11.71, 23.43, 46.87, 93.75, 187.5,
375, and 750 μg/ml (Carrio et al. 2000).
Parasite culture
L. tropica standard strain MHOM/IR/02/Mash2 was cul-
tured in NNN medium, incubated at 25°C±1°C and sub-
cultured in RPMI-1640 (Gibco, UK) supplemented with
15% heat-inactivated FCS, penicillin (200 IU/ml) and
streptomycin (200 μg/ml).
Promastigote assay
The susceptibility of promastigotes was carried out accord-
ing to the method described by Carrio et al. (2000). Serial
dilutions of MA in RPMI-1640 (PH, 7.2) were prepared in
96-well microtiter plate. Promastigotes (105) were har-
vested at log phase, and 100 μl of medium was added to
each well and incubated at 25°C±1°C for 72 h. Promasti-
gotes were cultured in medium with no drug and used as
positive control, and medium with no organism was used as
blank. All experiments were performed in triplicate. MTT
assay was performed by preparing MTT (Sigma Aldrich,
USA) in sterile PBS and 10 μl of MTT solution was added
in each well, incubated at 25°C±1°C for 3 h. The reaction
was stopped by using isopropanol alcohol and read by
ELIZA reader (ELX800) at 492 nm. IC50 was determined
using the following formula:
Log IC50 ¼ log x1 þ y1  y0=2
 
= y1  y2ð Þ
 
 log x2ð Þ  log x1ð Þ½ 
Amastigote assay
Macrophages were collected from Balb/c mouse by injecting
5 ml of cold RPMI-1640 medium into mouse peritoneal cavity;
aspirated macrophages were washed twice and resuspended in
RPMI-1640. The amastigote viability test was carried out
according to the method described elsewhere (Carrio et al.
2000). Every experiment was done in triplicate similar to
promastigote assay. Viability test was performed by adding
90 μl of trypan blue solution (0.2%) in saline containing
0.01% sodium aside to 10 μl of cell suspension (106cells per
milliliter). After 2 min, cells were counted under light
microscope, and viability was calculated as follows:
%Viability ¼ % of live cells =all counted cellsð Þ  100
Then, 200 μl of the cells (106cells per milliliter) was added
into 8-chamber slide (Lab-Tek, Nalge Nunc International NY,
USA), incubated at 37°C with 5% CO2 for 2 h. Promastigotes
were added to macrophages and incubated at 37°C with 5%
CO2 for 24 h. Then MA concentrations (10 μl) in medium as
added to the slides and incubated at 37°C for 72 h. Dried slides
were fixed with methanol, stained by Giemsa and studied
under light microscope. Macrophages containing amastigotes
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with no drugs and macrophages alone were considered as
positive and negative controls, respectively. Drug activity was
evaluated by counting the number of amastigotes in the
macrophages by examining 100 macrophages.
Statistical analysis
SPSS was used to analyze the data. ANOVA test was used to
define a possible relation between MA alone and MA plus
verapamil. The IC50 values ofMA alone andwith verapamil for
both promastigote and amastigote stages were compared using
t-test, and P<0.05 was considered as a significant difference.
Results
Promastigote assay
In promastigote form, several concentrations of MA with or
without verapamil showed significant decrease (P<0.05) in
optical density (OD) as measured by MTT method. The
mean OD for MA was 132.5±11.8, for MA plus verapamil
was 125±23.2, and for verapamil alone was 153.1±20.5
(Fig. 1). The overall growth rate of promastigotes treated
with various concentrations of MA plus V (IC50=116.03 μg/
ml) was significantly lower (P<0.05) than growth rate in
MA alone (IC50=225.14 μg/ml).
Amastigote assay
The effect of MA alone and with verapamil was
evaluated by the mean infection rate (MIR) of each
macrophage and also by the mean number of amasti-
gotes in each macrophage. Comparison of the MIR
showed that different concentrations of MA in absence
of verapamil significantly inhibited growth of macro-
phages by 187.5 μg/ml (P<0.05), whereas there was no
effect, thereafter, as compared with positive control
(Table 1). However, the effect of MA alone on the mean
number of amastigotes in each macrophage was signifi-
cant by 46.87 μg/ml (P<0.05), when compared with
positive control (P<0.05).
The effect of various concentrations of MA plus
verapamil or MA alone on the MIR reduced infection
rate by at least 23.43 μg/ml (Table 2), although,
infected macrophages failed to survive at 5.85 μg/ml of
MA plus verapamil. But, when the mean number of
amastigotes is being considered a significant difference
was observed at various concentrations of MA along
verapamil.
Analysis of overall effect of different concentrations of
MA alone, compared with combination of MA plus
verapamil by mean infection rate and mean number of
amastigotes in each macrophage is shown in Table 3. T-test
analysis indicated MA plus verapamil showed a synergistic
effect at concentrations of 375, 118.5, and 93.75 μg/ml as
compared with the respective concentrations of MA alone
when the MIR is considered.
Fig. 1 Comparison of optical density (OD) between positive control
(PC), verapamil (V), meglumine antimoniate (MA), and meglumine
antimoniate plus verapamil (MA + V) on the susceptibility of
promastigotes by colorimetric assay
Table 1 The effect of various
concentrations of meglumine
antimoniate (MA) alone on the
mean infection rate and number
of amastigotes per macrophage
in comparison with infected
macrophages with no treatment
as positive control
Mean infection rate Mean number of amastigote in each macrophage
Concentration Mean±SD P value Mean±SD P value
0 μg MA(control) 66.00±2.00 Not significant 3.54±0.24 Not significant
750 μg MA 50.66±6.65 p<0.001 2.05±0.10 p<0.001
375 μg MA 55.33±4.16 p<0.001 2.31±0.31 p<0.001
187.5 μg MA 59.00±2.64 p<0.05 2.74±0.20 p<0.01
93.75 μg MA 61.33±3.51 Not significant 2.84±0.21 p<0.01
46.87 μg MA 63.33±4.50 Not significant 2.99±0.29 p<0.05
23.43 μg MA 64.33±3.51 Not significant 3.15±0.31 Not significant
11.71 μg MA 66.00±3.60 Not significant 3.26±0.35 Not significant
5.85 μg MA 67.33±4.04 Not significant 3.43±0.44 Not significant
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Discussion
Despite effort and progress over the years, the number
of drugs available for treatment of CL remains limited.
MA is the treatment of leishmaniasis for nearly 65 years.
In addition to the low response recently reported against
various forms of leishmaniasis due to resistance (Croft
et al. 2006; Hadighi et al. 2006, 2007; Pour et al. 2011)
treatment with antimonials is long, painful, and associated
with toxicity (Alvar et al. 2006). In Iran, ACL due to L.
tropica is a chronic disease and at present combination of
treatment such as MA with cryotherapy or along with
other drugs are used (Khatami et al. 2007; Layegh et al.
2009; Modabber et al. 2007). Therefore, the need for new
drug development and treatment regimens, effective
against different forms, are highly recommended. Hope-
fully, there are promising new developments currently
used in drug treatment of leishmaniasis (Moreno et al.
2011; Shakya et al. 2011).
Most of the previous pre-clinical drug studies have been
concentrated on promastigotes of Leishmania species; in
vitro drug susceptibility experiments on both promastigote
and amastigote stages are fairly rare (Ranjini Valiathan et al.
2006). In the present study, the effect of verapamil as a
calcium channel blocker in combination with MA in the
growth of promastigote and amastigote stages of L. tropica
have been investigated. Various concentrations of MA along
with verapamil inhibited the growth of both stages of L.
tropica and caused significant response, as compared with
MA alone. It is shown that verapamil when used in
combination with chloroquine, enhances the accumulation
of chloroquine within a parasitic cell digestive vacuole,
rendering it incapable of detoxifying itself and making it
more susceptible to death (Martin et al. 1987).
The overall mean IC50 values of MA plus verapamil for
promastigote stage was significantly lower than those with
MA alone (P<0.05). Similarity, the amastigote stage was
more susceptible to treatment with MA plus verapamil,
compared to similar concentrations of MA alone. In
general, both amastigotes and promastigotes findings are
in agreement with others (Ranjini Valiathan et al. 2006).
However, they used clinical isolates and standard strain of
Leishmania donovani and showed that the amastigote stage
is 2–60 folds more sensitive to sodium stibogluconate than
Table 2 The effect of various
concentrations of meglumine
antimoniate (MA) plus verapamil
(V) or V alone on the mean
infection rate and number of
amastigotes per macrophage in
comparison with infected
macrophages with no treatment as
positive control
Mean infection rate Mean number of amastigote in each macrophage
Concentration Mean±SD P value Mean±SD P value
0 μg MA(control) 66.00±2.00 Not significant 3.54±0.24 Not significant
V alone(8 μg) 53.33±1.52 p<0.001 2.83±0.10 p<0.01
750 μg MA+V 43.66±2.50 p<0.001 2.06±0.33 p<0.001
375 μg MA+V 47.66±2.50 p<0.001 2.33±0.29 p<0.001
187.5 μg MA+V 51.00±1.00 p<0.001 2.45±0.29 p<0.001
93.75 μg MA+V 54.33±0.50 p<0.001 2.57±0.23 p<0.001
46.87 μg MA+V 59.33±1.15 p<0.001 2.74±0.14 p<0.001
23.43 μg MA+V 62.00±1.73 p<0.01 2.85±0.06 p<0.01
11.71 μg MA+V 63.66±1.50 Not significant 2.96±0.75 p<0.05
5.85 μg MA+V 65.66±1.15 Not significant 3.05±0.12 p<0.05
Table 3 Analysis of overall effect of different concentrations of meglumine antimoniate (MA) alone as compared with meglumine antimoniate
plus verapamil(V) by the mean infection rate and mean number of amastigotes in each macrophage
Concentration Mean infection rate Mean number of amastigote in each macrophage
Sig (two-tailed) Sig (two-tailed)
MA (750 μg/ml)& MA+V(750 μg/ml) 0.164 Not significant 0.963 Not significant
MA (375 μg/ml)&MA+V(375 μg/ml) 0.050 Significant 0.940 Not significant
MA (187.5 μg/ml)&MA+V(187.5 μg/ml) 0.008 Significant 0.235 Not significant
MA (93.75 μg/ml)&MA+V(93.75 μg/ml) 0.027 Significant 0.219 Not significant
MA (46.87 μg/ml)&MA+V(46.87 μg/ml) 0.211 Not significant 0.247 Not significant
MA (23.43 μg/ml)&MA+V(23.43 μg/ml) 0.360 Not significant 0.181 Not significant
MA(11.71 μg/ml)&MA+V(11.71 μg/ml) 0.360 Not significant 0.226 Not significant
MA (5.85 μg/ml)&MA+V(5.85 μg/ml) 0.530 Not significant 0.225 Not significant
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promastigote stage. There is a significant difference
between promastigotes in biochemistry and sensitivity to
standard and experimental drugs as indicated previously
(Lira et al. 1999). The effect of verapamil has already been
evaluated, as arsenite-resistant L. donovani promastigotes
express an enhanced membrane P-type adenosine triphos-
phatase activity that was sensitive to verapamil treatment
(Prasad et al. 2000).
Conclusion
The results of this study showed some degree of synergistic
effect of verapamil on MA in inhibiting growth of
promastigote and amastigote stages of L. tropica. Further
works are required to evaluate this synergistic effect on
animal model or volunteer human subjects.
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